| Document |
Document Title |
|
WO/2023/219071A1 |
Provided is a compound represented by formula (1).
|
|
WO/2023/215257A2 |
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
|
|
WO/2023/215234A2 |
Provided are luminescent organic compounds containing a benzoyl group covalently bonded to a pyrazine group, along with methods of synthesizing such compounds. The luminescent compounds can be used in organic light-emitting diodes (OLEDs...
|
|
WO/2023/208018A1 |
The present invention provides a substituted pyrimidine hydrazide compound represented by formula (I) or an optical isomer, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the substituted ...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/208130A1 |
Provided are a compound represented by general formula (I'), a method for preparing same, a pharmaceutical composition comprising same, and use thereof as a ubiquitin specific protease 1 (USP1) inhibitor, in particular, use thereof in tr...
|
|
WO/2023/208151A1 |
The present disclosure provides a compound which has an inhibitory effect on USP, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, as shown in formula (I), the definition of each group in the formula be...
|
|
WO/2023/211213A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport and injection ability, light-emitting abilit...
|
|
WO/2023/208171A1 |
Disclosed in the present invention are a PLpro protease inhibitor, and a preparation method and application thereof. The PLpro protease inhibitor can be combined with one or more pharmaceutically acceptable auxiliary materials or one or ...
|
|
WO/2023/203574A1 |
A process for preparation of azoxystrobin is provided. The process includes two different routes for preparing the azoxystrobin using catalyst selected from a group consisting of 4-methylmorpholine, 1,4-dimethylpiperazine, 2,2,6,6-tetram...
|
|
WO/2023/205463A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
|
|
WO/2023/199258A1 |
The present disclosure encompasses a solid state form of Mavacamten, in embodiments a crystalline polymorph of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/198181A1 |
Carbobicyclic nucleoside compounds useful for the treatment of coronavirus disease 2019 (COVID-19), RSV and other viral infections are provided. The carbobicyclic nucleoside compound may be a compound as set forth herein. Pharmaceutical ...
|
|
WO/2023/200641A1 |
The present disclosure relates to an isocyanate reactive composition for use in a polyurethane formulation and to methods of making polyurethane material from the polyurethane formulation. The isocyanate reactive composition generally in...
|
|
WO/2023/198484A1 |
The invention relates to an improved process for recovering N,N-Dimethylformamide (DMF) from an aqueous process stream by adjusting the pH, extracting with Chloroform and subsequent distillation/rectification.
|
|
WO/2023/195773A1 |
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative represented by chemical formula (I) and a pharmaceutical composition including same effectively suppress HER2 activity, and thus are usef...
|
|
WO/2023/193795A1 |
The present invention relates to a compound targeting focal adhesion kinase and a preparation method for and an application of the compound. The compound targeting focal adhesion kinase of the present invention has the following general ...
|
|
WO/2023/196629A1 |
The invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof; wherein Ra and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2- bridging moiety; A is -CH2- or -C(=O)-; T i...
|
|
WO/2023/194496A1 |
A process for the preparation of compound of formula (I) is provided: where R, R1, R2, R3 and R4 are as defined in the description.
|
|
WO/2023/196614A1 |
The disclosure provides compounds of Formulas (I), (I-2), (I-3), (I-4), (I-5), (II), (II-2), (II-3), (II-4), and (II-5) and pharmaceutically acceptable salts thereof. Also provided are compositions and methods of using the compounds, e.g...
|
|
WO/2023/186691A1 |
The invention relates to substituted 2-C-azines of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing...
|
|
WO/2023/186126A1 |
The present invention relates to an aromatic ring compound and use thereof. Specifically provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable sal...
|
|
WO/2023/187791A1 |
Compounds capable of activating an unfolded protein response (UPR) in a cell, for use in treating a viral infection in a subject in need thereof, are disclosed. The compounds can be PERK activators and/or compounds represented by Formula...
|
|
WO/2023/185831A1 |
The present application relates to a compound containing a thiazole ring, and specifically to a compound of formula I, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof in treating diseases such...
|
|
WO/2023/187697A1 |
The present invention relates to a process for the preparation of belumosudil mesylate and its crystalline form. Further, the present invention relates to a 10 pharmaceutical composition comprising a therapeutically effective amount of t...
|
|
WO/2023/192416A1 |
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2023/192502A1 |
The present invention provides spirobicyclic compounds, particularly a compound of formula (I) and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I in treating diseases associat...
|
|
WO/2023/186690A1 |
The invention relates to substituted 2-aminoazines of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influenc...
|
|
WO/2023/185597A1 |
Disclosed in the present invention are a Letermovir intermediate and a preparation method therefor. Specifically, the method comprises the step of: crystallizing methyl {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy
-5-(tri...
|
|
WO/2023/187783A1 |
Newly designed compounds represented by Formulae I-V as described in the instant specification and uses thereof as pancreatic endoplasmic reticulum kinase (PERK) activators and in treating associated medical conditions, including viral i...
|
|
WO/2023/178693A1 |
Provided in the present invention is a method for preparing lemborexant, which method comprises the following steps: subjecting compound II and compound III as raw materials to a reaction in a second reaction solvent to obtain lemborexan...
|
|
WO/2023/182530A1 |
Obtained is an excellent anti-CD39 antibody. Provided is an antibody or an antigen-binding fragment that binds to CD39, and contains heavy-chain CDRs 1-3 and light-chain CDRs 1-3 containing a specific amino acid sequence. This antibody m...
|
|
WO/2023/175184A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, or pharmaceutically acceptable salt thereof. The prese...
|
|
WO/2023/175185A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form or a pharmaceutically acceptable salt thereof. The pres...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/172112A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising the compound.
|
|
WO/2023/168298A2 |
The present disclosure relates generally to small molecule inhibitors of Sterile Alpha and TIR Motif containing 1 (SARM1) protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomer...
|
|
WO/2023/165334A1 |
The present invention provides keto amide derivatives and the pharmaceutical use thereof, belonging to the technical field of organic synthesis drugs. Specifically provided are a compound represented by formula I, or a pharmaceutically a...
|
|
WO/2023/166103A1 |
The present invention relates to compounds of formula (I), wherein R1 to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the ...
|
|
WO/2023/166153A1 |
There is provided a compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
|
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
|
WO/2023/160011A1 |
Disclosed are a β‑Elemene derivative containing an N-OH bond, a preparation method therefor and a use thereof. The present invention provides a class of β‑Elemene derivatives containing an N-OH bond having the structure shown in fo...
|
|
WO/2023/161172A1 |
The present invention relates to substituted N-benzoic acid uracils of general formula (I) or salts thereof, wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof as he...
|
|
WO/2023/164464A1 |
The present disclosure provides phosphate mimic derivatives of Formula (I) or (II): (I); (II); pharmaceutically acceptable salts thereof, and related Nucleic Acid Agents and conjugates. The present disclosure also relates to uses of the ...
|
|
WO/2023/159794A1 |
Provided is a 2,4-diaminopyrimidine oxide preparation method. The preparation method comprises the following steps: carrying out a cyclization reaction on 3-oxopropionitrile and guanidine under an oxidation condition to produce 2,4-diami...
|
|
WO/2023/164596A1 |
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the...
|
|
WO/2023/159155A1 |
Disclosed herein are compounds of Formulae 1A, 1B, 1C and 1D, (1A), (1B), (1C) and (1D) and methods of making and methods of using the same.
|
|
WO/2023/156386A2 |
A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic grou...
|
|
WO/2023/151662A1 |
Provided are an androgen receptor activity regulator and the use thereof. The androgen receptor activity regulator has a structure as represented by formula 1-I or formula 2-I, wherein R1-R7, X, ring A, ring B, ring C, n, m, p, Z1 and Z2...
|
